Form 8-K - Current report:
SEC Accession No. 0001193125-25-153582
Filing Date
2025-07-01
Accepted
2025-07-01 09:25:34
Documents
14
Period of Report
2025-07-01
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.01: Changes in Control of Registrant
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d90696d8k.htm   iXBRL 8-K 46389
2 EX-3.1 d90696dex31.htm EX-3.1 8506
3 EX-3.2 d90696dex32.htm EX-3.2 107333
  Complete submission text file 0001193125-25-153582.txt   322237

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA inzy-20250701.xsd EX-101.SCH 2849
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE inzy-20250701_lab.xml EX-101.LAB 19481
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inzy-20250701_pre.xml EX-101.PRE 12152
16 EXTRACTED XBRL INSTANCE DOCUMENT d90696d8k_htm.xml XML 3969
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Filer) CIK: 0001693011 (see all company filings)

EIN.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39397 | Film No.: 251094406
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)